Date Name Title Filing Type Shares Traded Price Total Held
May 17, 2004
Director
Director Form 4 Bona fide gift 200,000 -- 62,360
May 17, 2004
Director
Director Form 4 Bona fide gift 200,000 -- 200,000
May 13, 2024
Director, Bd. Co-Chair, President & CEO
Director, Bd. Co-Chair, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 203,204 $399.66 577,633
May 13, 2024
Director, Bd. Co-Chair, President & CEO
Director, Bd. Co-Chair, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 203,204 -- --
Dec 16, 2014
Director, President & CEO
Director, President & CEO Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 203,204 -- 203,204
Dec 13, 2013
Director, Pres Regeneron Labs
Director, Pres Regeneron Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 203,204 -- 203,204
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- 213,693
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- --
Sep 18, 2013
Director, President & CEO
Director, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 218,389 $9.49 260,476
Sep 18, 2013
Director, President & CEO
Director, President & CEO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 218,389 -- --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.